CD19-directed chimeric antigen receptor t cell therapy has been studied in 1 paper since 2026: 1 observational study in people; 1 in the past year. The newest story, Nov 2, 2026: “Blood-cell clones linked to complications after lymphoma therapy”.
1 paper studies it2 findingsUpdated
1 new paper in 30 daysSee all 1
“CAR19-treated patients exhibited impaired immune reconstitution and increased infection.”
None of its findings points the other way.
Studies link CD19-directed chimeric antigen receptor t cell therapy with 2 measures, most often clonal hematopoiesis (1 study) and infection (1).
Clonal hematopoiesis
upin humans1
CD19-directed chimeric antigen receptor t cell therapy is associated with clonal hematopoiesis in humans Following CAR19 infusion in patients with lymphoma.
“Clonal hematopoiesis (CH) commonly expanded following CAR19 infusion”
HumansFollowing CAR19 infusion in patients with lymphoma
Blood-cell clones linked to complications after lymphoma therapy
Nature genetics
Infection
upin humans1
CD19-directed chimeric antigen receptor t cell therapy is associated with infection in humans.
“CAR19-treated patients exhibited impaired immune reconstitution and increased infection.”
HumansPatients with lymphoma; compared with propensity-matched autologous hematopoietic cell transplantation controls
Blood-cell clones linked to complications after lymphoma therapy
Nature genetics
An observational study in patients with lymphoma linked expanding blood-cell clones to poorer immune recovery and treatment-related blood cancers after engineered…An observational study in patients with lymphoma linked expanding blood-cell clones to poorer immune recovery and treatment-related blood cancers after engineered immune-cell therapy.